-+ 0.00%
-+ 0.00%
-+ 0.00%

Aspire Biopharma amends 8-K to correct disclosure inaccuracies on preferred stock offering

PUBT·04/17/2026 10:11:23
Listen to the news
Aspire Biopharma amends 8-K to correct disclosure inaccuracies on preferred stock offering
  • Aspire Biopharma filed an amended Form 8-K to amend and restate an April 16, 2026 report to correct disclosure inaccuracies.
  • Amendment updated disclosure on closing of second tranche of private placement of Series A Convertible Preferred Stock on April 15, 2026 for 12,500 shares with gross proceeds of about USD 10 million.
  • Filing also clarified Series A Convertible Preferred Stock authorization to 30,000 shares with stated value of USD 1,000 per share.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-017145), on April 17, 2026, and is solely responsible for the information contained therein.